Free tool
FAERS Monitor: Nivestym
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761080 or its brand name (Nivestym, Filgrastim-Aafi). Reports on generic versions are filed under their own applications.
Reports
669
Serious
400
60% of reports
Hospitalization
190
Death reported
116
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death94
- off label use84
- white blood cell count decreased38
- pyrexia25
- hospitalisation24
- fatigue23
- diarrhoea22
- pain21
- malaise19
- device leakage18
- needle issue18
- bone pain17
- dyspnoea17
- product dose omission issue17
- infection15
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 24 |
| 2020 | 66 |
| 2021 | 77 |
| 2022 | 106 |
| 2023 | 122 |
| 2024 | 99 |
| 2025 | 93 |
| 2026 | 82 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,490 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| needle issueSignal | 18 | 19.5 | 12.3 | 297 |
| device leakageSignal | 18 | 13.1 | 8.3 | 189 |
| white blood cell count decreasedSignal | 38 | 11.0 | 8.1 | 338 |
| bone painSignal | 17 | 9.1 | 5.7 | 115 |
| hospitalisationSignal | 24 | 4.9 | 3.3 | 71 |
| deathSignal | 94 | 3.4 | 2.8 | 166 |
| infectionSignal | 15 | 3.3 | 2.0 | 21 |
| off label useSignal | 84 | 3.0 | 2.5 | 116 |
| pyrexiaSignal | 25 | 2.3 | 1.5 | 17 |
| product dose omission issue | 17 | 1.8 | 1.1 | 6 |
| malaise | 19 | 1.4 | 0.9 | 2 |
| pain | 21 | 1.1 | 0.7 | 0 |
| diarrhoea | 22 | 1.1 | 0.7 | 0 |
| dyspnoea | 17 | 0.9 | 0.6 | 0 |
| fatigue | 23 | 0.9 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.